Gaurav Dhanda, PharmD
MediMedia Managed Markets

Gaurav Dhanda, PharmD is a Clinical Services Manager at MediMedi Managed Markets and a former community pharmacist.

A few weeks ago, the U.S. Department of Health and Human Services made a final rule on a policy that implemented incentive payment provisions in the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). This rule, which takes effect January 2017, has huge potential to change the health care market.

The current system is based on a sustainable growth-rate formula which is very confusing and does not help cut costs where physicians are able to charge on a fee-for-services basis. This means that prescribers get paid more for more services that they provide. However, the services that they provide aren’t of the highest quality and cost of health care has been rising. According to the PBS newswire, the cost per person for health care is projected to exceed $10,000 per person this year. With costs increasing and quality diminishing, a change had to be made.

The final rule incorporated two different reimbursement pathways for physicians to participate in which are a merit-based incentive payment system (MIPS), and an advanced alternative payment model (APM). These new methods create incentive for physicians to provide quality care in order to receive annual bonuses and avoid penalties.  

According to CMS, under MIPS, clinicians would be paid based on performance in four categories of quality, cost, improvement activity, and “advancing care information,” which is the use of health information technology. For physicians that are included in this system, they would be eligible to receive plus or minus 4% reimbursement in 2019 and will possibly go up to 9% in 2022.

Physicians who choose to opt out of MIPS must join an APM. These APMs are based upon partnerships between clinicians who may treat a specific population or a certain condition. Physicians under APMs are excluded from MIPS reporting requirements and payment adjustments, given that they adequately take part in an APM. APMs have requirements which include the use of electronic health records, service quality measures, and others. CMS is making many changes to the scope of Accountable Care Organizations (ACOs), which are considered to be APMs. Health care professionals who are a part of an APM are qualified for a 5% incentive payment.

CMS estimates that 70,000 to 120,000 clinicians will join APMs in 2017 as well as 500,000 clinicians participating in MIPS. Clinicians do not have to start gathering data by Jan. 1, 2017, but must choose a start date between Jan. 1 and Oct. 2, 2017. Data must be sent by March 31, 2018 and the first payment adjustment will go in effect on Jan. 1, 2019.

The goal of these new pathways seems to focus on quality of care. I feel that the pressure is now on clinicians and health care groups to provide quality care, not quantity care. It may be a while until we see the effects of the ruling and if cost of health care does go down. 

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.